Everads specializes in developing suprachoroidal delivery technology for ocular gene therapy, as self-described in various announcements regarding their innovations and clinical trials.

Everads

Everads Therapy Ltd | 290 followers on LinkedIn. Optimizing Treatment of Retinal Disease by Leveraging Novel Delivery Technology | Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads&#39; delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel.

Hagay Drori

Executive Chairman at Everads Therapy and CEO at Moebius Medical Ltd.

Moshe Weinstein

Drug delivery design expert | Medical devices entrepreneur

Lior Raday

Clinical Operations Expert

Adi Bigger Hoggeg

Everads Therapy Ltd

💫 Everads is excited to announce that it was selected as the top startup at the Eye and Beyond II conference hosted by the Ophthalmology Division of the Rabin Medical Center. Congratulations to Keren Mano-Tamir (M.D / MBA) for this great achievement! 👏 #ophthalmology #suprachoroidal #drugdelivery #genetherapy #everads

Everads is excited to have initial clinical data using our suprachoroidal delivery technology presented at EURETINA. Congratulations to Dr. Y Barak, Head of Retina and Rambam Medical Center, for this achievement! #opthalmology #suprachoroidal #drugdelivery #genetherapy https://lnkd.in/dDdGz7E8

I am excited to share that Everads will be leading the Suprachoroidal Delivery Workshop at the gene therapy for ophthalmic disorders summit. See you there!

Everads is happy to share that the ability of our suprachoroidal delivery technology to delivery AAV-based gene therapy to the back of the eye is being presented today by Dr. Yoreh Barak of Rambam Medical Center at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. For those at ARVO, please come by poster B0029 3:30-5:15pm! #opthalmology #suprachoroidal #drugdelivery #genetherapy

Our CEO Moshe Weinstein will be sharing updates regarding Everads and our suprachoroidal delivery platform this week at 2nd Next Generation Ophthalmic Drug Delivery conference. We look forward to seeing you there!

Metric
Company Name	Everads
Symbol
MSH ID	COM:EVERADS-THERAPY
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	IL
Stage
Employee Count
Website	everads-therapy.com
LinkedIn	everads-therapy
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

EVER

COM:EVERADS-THERAPY

Everads

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue